Biopharma royalty deals are on the rise
This issue of our newsletter is supported by Inpart.
A spate of recent royalty deals suggests that certain biotech companies are changing the way they press ahead.
In fact, this is now a trend that seems to be a gradual alternative to traditional biopharma fundraising.
A recent example that has followed this trend is Cytokinetics’ $575 million pact with Royalty Pharma, a firm that buys up royalties from life science companies.
But, while these deals may be for the better for some players in the industry, others may have a lot to lose.
To find out more, read the full article: “Moving with the times: biopharma royalty deals on the rise”
A MESSAGE FROM OUR SPONSOR INPART
R&D trends and breakthrough innovations in respiratory disease
Download the free report surfacing data from Inpart’s online partnering platform, Connect, to identify the most promising early-stage projects and assets with the highest demand by industry.
The report also contains a snapshot into industry sentiment about the respiratory disease market, and a listing of the most active institutes to engage with.
🔥 More noteworthy articles from this week:
Recommended by LinkedIn
Hearing loss affects more than a billion people worldwide, but recent advancements in healthcare - particular with regard to regenerative cell therapy - mean that, after decades of research, stem cell therapy could treat hearing loss.
Unlike autologous cell therapy, where the patient’s own cells are used, allogeneic cell therapy companies leverage donor cells, which can come from various sources such as bone marrow or umbilical cord blood. In this article, we discover at eight allogeneic cell therapy companies.
Recruitment is essential for generating data on drug efficacy. However, the landscape of clinical trial recruitment is becoming increasingly competitive and the task of recruiting participants has never been more challenging. So, what is being done to transform trial recruitment?
If you are investing in biotech stocks, you will be faced with the challenge of finding the right price for a company’s shares. While there is no single formula that can condense the multiple parameters influencing a biotech stock, Labiotech asked experts to share their most reliable valuation methods.
While biotech in the Balkans is still developing, particularly with regard to healthcare, various countries within the Balkans are beginning to embrace their life sciences sectors, developing hubs to attract more attention and accelerate local innovation. In this article, we take a look at five biotech companies in the Balkans.
This week, Labiotech spoke to Anders Essen-Möller, founder and chairman of Diamyd Medical, about treatments of type 1 diabetes, including the company’s development of Diamyd, an antigen-specific immunomodulatory therapeutic for the preservation of endogenous insulin production.
With a comprehensive suite of services tailored to support cell and gene therapies (CGT) research and development, Cryoport Systems is expanding its presence in Europe to meet escalating market demands. As demand surges, overcoming challenges becomes pivotal, highlighting the imperative of strategic collaborations with industry-leading partners as the CGT market continues to grow at an unprecedented pace.
💡Enjoying these articles? Never miss a single publication of Labiotech by becoming a part of our community! Click here to join our mailing list.